Multiple myeloma (MM) is characterized by the expansion of malignant plasma cells in the
bone marrow. These transformed plasma cells are highly biosynthetic thereby producing …

The natural history of multiple myeloma (MM) has profoundly changed over the last 20
years, largely due to the introduction of novel agents targeting MM in the context of the bone …

Multiple myeloma (MM) is the prototypic cancer model for proteotoxicity due to the extensive
and sustained synthesis of immunoglobulin or free light chain in the face of insufficient …

Multiple myeloma (MM) is a hematological malignancy characterized by the dysregulated
proliferation of transformed plasma cells (PCs) primarily in the bone marrow (BM)(1). For the …

In an original preclinical study published in this issue of Blood Advances, Li et al 1 provide
proof-ofprinciple evidence of the therapeutic efficacy of a novel approach against multiple …

Multiple myeloma (MM) is a malignancy of terminally differentiated B-lymphocytes that
accounts for∼ 13% of all hematologic cancers. Despite a wealth of knowledge describing …

Introduction: Remarkable progress in molecular characterization methods has led to
significant improvements in how we manage multiple myeloma (MM). The introduction of …

Multiple myeloma (MM) is an incurable hematologic malignancy. Most MM patients are
diagnosed at a late stage because the early symptoms of the disease can be uncertain and …

Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B
lymphocytes. Like other types of cancers, myeloma cells have acquired functional …

Multiple myeloma is an incurable cancer of plasma cells that is predominantly located in the
bone marrow. Multiple myeloma cells are characterized by distinctive biological features that …